CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Files An 8-K Other Events
Item 8.01 Other Events.
On February 23, 2017, Cyclacel Pharmaceuticals, Inc. issued a
press release announcing top-line results from its pivotal Phase
3 SEAMLESS study in elderly patients aged 70 years or older with
newly diagnosed acute myeloid leukemia (AML), who are not
candidates for or have refused intensive induction chemotherapy.
A copy of the press release is attached as Exhibit99.1 to this
Current Report on Form 8-K, and the information contained therein
is incorporated herein by reference.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits
| Exhibit Number | Description | |
| 99.1 | Press release, dated February 23, 2017 |
About CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC)
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors. CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Recent Trading Information
CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) closed its last trading session 00.00 at 5.44 with 25,487 shares trading hands.
